EUVIMEDEUVIMED entdecken
Crossref

A Progression‐Associated Tumor‐Reactive T‐Cell Signature Predicts Immunotherapy Response and Reveals ICOS‐High CD8 T‐Cell Functional States in Head and Neck Squamous Cell Carcinoma

Shaoqian Zhang iD, Xiaotong Yan, Xichen Dong iD, Changming An iD, Tao Gu, Tao Wen

Molecular Carcinogenesis · 2026-12 · 65 (12) · 1638-1662

DOI: 10.1002/mc.70185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 27.09.2026. Verfasst von Shaoqian Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Inducible T-Cell Co-Stimulator Protein, Immunotherapy, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade has improved outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but reliable biomarkers for predicting therapeutic response remain limited. Tumor‐reactive T‐cell states are increasingly recognized as critical determinants of antitumor immunity; however, progression‐associated T‐cell programs that reflect tumor evolution and predict immunotherapy benefit remain insufficiently characterized. We integrated single‐cell transcriptomic and T‐cell receptor (TCR) sequencing data from HPV‐negative HNSCC progression models to identify T‐cell genes associated with tumor progression and TCR‐supported immune states. Candidate genes were further refined using pretreatment immunotherapy cohorts, and a five‐gene signature (HNSC‐TstcSig) was established using survival and response‐associated analyses. The predictive performance of HNSC‐TstcSig was evaluated across multiple immunotherapy cohorts, including HNSCC and melanoma data sets. Single‐cell transcriptomic analyses, spatial transcriptomic analysis, and multiplex immunofluorescence were performed to characterize the biological features of HNSC‐TstcSig‐associated immune states. In addition, machine learning‐based survival modeling was conducted to identify genes shared between immunotherapy response and natural prognosis. HNSC‐TstcSig, consisting of GBP2, HAVCR2, ETV7, ICOS, and IL2RA, showed consistent associations with immunotherapy response across multiple cohorts and reflected an immune‐inflamed tumor microenvironment characterized by enhanced immune infiltration, T‐cell activation, and immune checkpoint‐related programs. Single‐cell analyses revealed that HNSC‐TstcSig genes were predominantly enriched in activated CD8 T‐cell populations and were associated with cytotoxic and inflammatory immune states. Among the signature genes, ICOS showed consistent associations with CD8 T‐cell activation, cytotoxicity, and immune checkpoint‐related features. Network perturbation analysis further suggested that ICOS was connected with transcriptional programs involved in T‐cell functional regulation. Spatial transcriptomic analysis and multiplex immunofluorescence further supported the association between ICOS‐related immune features and tumor immune activity at the tissue level. Furthermore, a machine learning‐derived natural prognostic model identified ICOS as a shared gene linking immunotherapy response and survival outcomes. We developed a progression‐associated T‐cell signature, HNSC‐TstcSig, that predicts immunotherapy response and reflects immune‐active tumor states in HNSCC. Our findings suggest that ICOS is associated with a tumor‐reactive CD8 T‐cell state characterized by cytotoxic activity and immune checkpoint‐related features, providing a potential biomarker for immune stratification and a framework for understanding T‐cell states associated with therapeutic benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesInducible T-Cell Co-Stimulator ProteinImmunotherapySquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsBiomarkers, TumorHumansPrognosisDisease ProgressionGene Expression Regulation, NeoplasticGene Expression ProfilingTranscriptome

Substanzen

Inducible T-Cell Co-Stimulator ProteinICOS protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei Province, China.

ORCID-Profile: Shaoqian Zhang, Xichen Dong, Changming An

Förderung

  • National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research

Zitieren

APA

Zhang, S., Yan, X., Dong, X., An, C., Gu, T., & Wen, T. (2026). A Progression‐Associated Tumor‐Reactive T‐Cell Signature Predicts Immunotherapy Response and Reveals ICOS‐High CD8 T‐Cell Functional States in Head and Neck Squamous Cell Carcinoma. Molecular Carcinogenesis, 65(12), 1638-1662. https://doi.org/10.1002/mc.70185

Vancouver

Zhang S, Yan X, Dong X, An C, Gu T, Wen T. A Progression‐Associated Tumor‐Reactive T‐Cell Signature Predicts Immunotherapy Response and Reveals ICOS‐High CD8 T‐Cell Functional States in Head and Neck Squamous Cell Carcinoma. Molecular Carcinogenesis. 2026;65(12):1638-1662. doi:10.1002/mc.70185

BibTeX
@article{Zhang2026,
  author = {Zhang, Shaoqian and Yan, Xiaotong and Dong, Xichen and An, Changming and Gu, Tao and Wen, Tao},
  title = {A Progression‐Associated Tumor‐Reactive T‐Cell Signature Predicts Immunotherapy Response and Reveals ICOS‐High CD8 T‐Cell Functional States in Head and Neck Squamous Cell Carcinoma},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  volume = {65},
  number = {12},
  pages = {1638--1662},
  doi = {10.1002/mc.70185}
}
Kostenlos starten →